Dongfang Baitai was invited to the Biomedical Hundred People Forum to discuss the new policy of medicine to drive industrial innovation!
- Categories:Company News
- Author:
- Origin:Dongfang Baitai
- Time of issue:2022-05-23
- Views:637
(Summary description)On November 24, 2018, the Biomedical Hundred Talents Forum, jointly held by the National Health and Family Planning Commission Medical and Health Science and Technology Development Research Center and the Beijing Science and Technology Cooperation Center and the Beijing Society of Biotechnology, opened in Beijing. Bai Yi, General Manager of Beijing Dongfang Baitai Biotechnology Co., Ltd., was invited to attend and speak.
Dongfang Baitai was invited to the Biomedical Hundred People Forum to discuss the new policy of medicine to drive industrial innovation!
(Summary description)On November 24, 2018, the Biomedical Hundred Talents Forum, jointly held by the National Health and Family Planning Commission Medical and Health Science and Technology Development Research Center and the Beijing Science and Technology Cooperation Center and the Beijing Society of Biotechnology, opened in Beijing. Bai Yi, General Manager of Beijing Dongfang Baitai Biotechnology Co., Ltd., was invited to attend and speak.
- Categories:Company News
- Author:
- Origin:Dongfang Baitai
- Time of issue:2022-05-23
- Views:637
On November 24, 2018, the Biomedical Hundred Talents Forum, jointly held by the National Health and Family Planning Commission Medical and Health Science and Technology Development Research Center and the Beijing Science and Technology Cooperation Center and the Beijing Society of Biotechnology, opened in Beijing. Bai Yi, General Manager of Beijing Dongfang Baitai Biotechnology Co., Ltd., was invited to attend and speak.
The theme of this year's forum is "new policies of medicine drive industrial innovation". Shen Yan, academician of the CAS Member, vice chairman of the Chinese Association for Science and Technology, and chairman of the Beijing Society of Biotechnology, served as the chairman of the forum, Wang Yu, former director of the Chinese Center for Disease Control and Prevention, distinguished professor of the Health City Research Center of Tsinghua University, and Li Qing, director of the Health Development Research Center of the National Health and Family Planning Commission, served as the executive chairman of the forum, and invited several leaders of relevant government functional departments, senior experts in the industry, and experts from well-known medical research and development institutions, People in the field of financial investment and pharmaceutical entrepreneurs. Together, we will interpret and understand the essence of the new national drug management policy, gain insight into industry trends, and share strategic wisdom.
The forum takes the gathering of domestic and foreign intellectual resources in the field of biomedicine as the starting point to build an innovative wisdom sharing platform of "learning, research, enterprise, medicine, government and capital" in the field of biomedicine. Focusing on the urgent and cutting-edge issues that are universally concerned by the industry, the forum created a grand gathering of 100 people with important academic influence in the industry to help the innovation and progress of the biomedical industry.
The policy interpretation section of the meeting explained and discussed the new policies on drug review, evaluation and supervision under the new medical reform situation, the national essential drug catalog and its price negotiation guidelines, several new policies on the research, approval and supervision of biological therapy products and technologies, the reform and new policies of the medical insurance system under the new medical reform situation, and the scientific and technological projects of "major new drug innovation" and their new strategic layout.
Some guests made speeches with the themes of "New Thinking and New Strategy of New Drug Innovation and Development", "Development Status and Competition Focus of Global Bio pharmaceutical Industry", and "Investment Status and Innovation Rise in China's Bio pharmaceutical Industry".
Bai Yi, General Manager of Dongfang Baitai, delivered a speech on the "Practical Bottlenecks and Obstacles to the Innovation and Development of China's Pharmaceutical Industry" on the panel of special discussion. Bai Yi first introduced Dongfang Baitai and its subsidiary Baitai Bio.
Dongfang Baitai was founded in 2011. It is located in Yizhuang Economic and Technological Development Zone. It is a high-tech enterprise engaged in the research, development and production of innovative antibody drugs. The company focuses on new products of major disease treatment and preventive biological medicine. The company has built an industrial technology platform with world advanced level, focusing on original antibody drugs and new vaccines, and running through the whole process of R&D and production. Nearly 20 R&D pipelines have been deployed in the treatment of major diseases such as cancer, diabetes and autoimmune diseases, among which 6 products are under clinical research.
Baitai Biopharmaceutical Co., Ltd., a subsidiary of Oriental Baitai, is the earliest enterprise engaged in antibody drug development in China. It has built the first world level humanized antibody technology platform in China. The first full-automatic large-scale mammalian cell culture production line in China was designed and built. It has the largest 4000L antibody perfusion industrialization system in the world. The core product, Taixinsheng, is the first humanized monoclonal antibody targeting drug on the market in China, which has good therapeutic effects on head and neck cancer, nasopharyngeal cancer, pancreatic cancer, breast cancer, glioma, non-small cell lung cancer and other cancers. Tai Xin joined the Chinese Pharmacopoeia in 2015 and was included in the national medical insurance in 2017. The project of "Development of Mammalian Cell Large scale Perfusion Culture Technology and Industrialized Application of Antibody" completed by the company won the highest science and technology award of Beijing Municipal Government and the first prize of Beijing Science and Technology Award. It has made certain contributions to the biomedical antibody field in China!
Then Bai Yi successively elaborated on the important bottleneck problems and relevant suggestions that Dongfang Baitai encountered in its own development process, such as the shortage of patient resources in domestic clinical trials, the shortage of resources in clinical trial institutions, and the excessive duplication of biological imitations of some targets, which limit drug innovation.
After the forum, Bai Yi, together with many guests and industry experts, discussed the development trend and difficulties of domestic and foreign pharmaceutical industry. Dongfang Baitai is willing to seize the development opportunities with many colleagues in the biopharmaceutical industry, jointly meet the new challenges of the innovative development of the pharmaceutical industry, and make new contributions to the innovative research and industrial development of biotechnology!
Scan the QR code to read on your phone
推荐新闻
Follow us

Follow the official WeChat official account
Or search "Oriental Baitai"
More exciting waiting for you!
Address: No. 2, Rongjing East Street, Beijing Economic and Technological Development Zone
Tel.: 010-51571019
Email: ebt@east-bt.com
Copyright 2021 Beijing Dongfang Baitai Biotechnology Co., Ltd SEO 京ICP备********号